Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

10.62
Delayed Data
As of Feb 17
 +0.08 / +0.76%
Today’s Change
3.80
Today|||52-Week Range
10.84
+22.92%
Year-to-Date

Today’s Trading

Previous close10.54
Today’s open10.53
Day’s range10.33 - 10.84
Volume13,149,855
Average volume (3 months)1,303,020
Market cap$743.9M
Dividend yield--
Data as of 3:59pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)-1,033.33%
Earnings growth (this year)+112.95%
Earnings growth (next 5 years)+7.00%
Revenue growth (last year)-80.45%
P/E ratio66.4
Price/Sales49.26
Price/Book8.21

Competitors

 Today’s
change
Today’s
% change
MGNXMacroGenics Inc+0.30+1.42%
HRTXHeron Therapeutics I...-0.30-2.05%
ACRSAclaris Therapeutics...+0.41+1.49%
AKAOAchaogen Inc+0.68+3.09%
Data as of 4:00pm ET, 02/17/2017

Financials

Next reporting dateMarch 16, 2017
EPS forecast (this quarter)-$0.19
Annual revenue (last year)$8.7M
Annual profit (last year)-$39.1M
Net profit margin-450.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark Robert Baker
Vice President-
Operations
Meryl J. Longval
Corporate headquarters
Tarrytown, New York

Forecasts


Search for Jobs